{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:21:32Z","timestamp":1789690892278,"version":"4.0.1"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular targets have been identified, both in monotherapy and in combination with peginterferon alpha (PegIFN\u03b1). Evaluating this review of the literature of the last ten years, HDV-related chronic hepatitis seems to have become a potentially curable disease, a statement that was unthinkable a few years ago. There are old and new weapons at our disposal. The old weapons are PegIFN\u03b1 and recently PegIFN-lambda (PegIFN\u03bb). PegIFN\u03b1, for which there are more data, appears to be an excellent combination regimen, if not contraindicated, both for Bulevirtide (BLV), data supported by important clinical trials and real-world studies, and probably for lonarfanib, although in the latter case the results are not yet definitive as the studies are fewer. However, data on long-term follow-up are needed.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1382017","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T07:03:13Z","timestamp":1739257393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Current and future therapeutic options for chronic hepatitis D virus infection"],"prefix":"10.3389","volume":"14","author":[{"given":"Mariantonietta","family":"Pisaturo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierantonio","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","article-title":"Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial","volume":"8","author":"Abbas","year":"2016","journal-title":"World J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104995","article-title":"Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis","volume":"185","author":"Abdrakhman","year":"2021","journal-title":"Antiviral Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/liv.15745","article-title":"Five-year follow-up of 96\u2009weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D","volume":"44","author":"Anastasiou","year":"2024","journal-title":"Liver Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S0168","DOI":"10.1016\/j.jhep.2022.12.023","article-title":"A 3-year course of bulevirtide monotherapy may cure hdv infection in cirrhotics","volume":"78","author":"Anolli","year":"2023","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.01.012","article-title":"Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)","volume":"55","author":"Anolli","year":"2023","journal-title":"Digestive Liver Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.24366","article-title":"Pegylated Interferon \u03b1 Therapy in Chronic Delta Hepatitis: A One-Center Experience","volume":"15","author":"Bahcecioglu","year":"2015","journal-title":"Hepat Mon."},{"key":"B10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/liv.15330","article-title":"T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide","volume":"42","author":"Behrendt","year":"2022","journal-title":"Liver Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/jmv.25438","article-title":"Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis","volume":"91","author":"Boglione","year":"2019","journal-title":"J. Med. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2016.03.017","article-title":"Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir","volume":"46","author":"Borzacov","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.dld.2023.01.143","article-title":"Bulevirtide improves health related qualitylife measured by EQ-5D VASin patients with chronic hepatitisdelta: an exploratory analysis of a phase 3 trial at 48 weeks","volume":"53","author":"Buti","year":"2023","journal-title":"Digestive Liver Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"8490","DOI":"10.1073\/pnas.88.19.8490","article-title":"The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus","volume":"88","author":"Chang","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/hiv.13518","article-title":"Real world\u201d efficacy of bulevirtide in HBV\/HDV-related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy","volume":"24","author":"Comandini","year":"2023","journal-title":"HIV Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2019","journal-title":"J. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/gastro\/goz023","article-title":"Hepatitis D infection: from initial discovery to current investigational therapies","volume":"7","author":"Da","year":"2019","journal-title":"Gastroenterol. Rep. (Oxf)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/S0168-8278(23)00593-7","article-title":"Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)","volume":"78","author":"Degasperi","year":"2023","journal-title":"J. HepatologyVolume"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S1159","DOI":"10.1016\/S0168-8278(23)03296-8","article-title":"Pretreatment and on-therapy HDV RNA levels predict response to Bulevirtide monotherapy in HDV compensated cirrhotic patients treated up to 96 weeks","volume":"781","author":"Degasperi","year":"2023","journal-title":"J. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/S0168-8278(23)00594-9","article-title":"Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease","volume":"78","author":"Dietz-Fricke","year":"2023","journal-title":"J. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100686","article-title":"Treating hepatitis D with bulevirtide - Real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1089\/jir.2010.0078","article-title":"Interferon-lambda: a new addition to an old family","volume":"30","author":"Donnelly","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion","year":"2023","journal-title":"Hepatology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0032-1323628","article-title":"Clinical features of hepatitis D","volume":"32","author":"Farci","year":"2012","journal-title":"Semin. Liver Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/infdis\/155.5.931","article-title":"Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B","volume":"155","author":"Fattovich","year":"1987","journal-title":"J. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B","volume":"46","author":"Fattovich","year":"2000","journal-title":"Eur. Concerted Action Viral Hepatitis (Eurohep). Gut."},{"key":"B32","unstructured":"Chronic hepatitis D virus infection: developing drugs for treatment\n          \n          2019"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1172\/JCI117091","article-title":"Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+\/bile acid cotransporter","volume":"93","author":"Hagenbuch","year":"1994","journal-title":"J. Clin. Invest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11050517","article-title":"Efficacy and safety of bulevirtide plus tenofovir disoproxil fumarate in real-world patients with chronic hepatitis B and D co-infection","volume":"11","author":"Herta","year":"2022","journal-title":"Pathogens."},{"key":"B37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2023.04.027","article-title":"No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta","volume":"79","author":"Hollnberger","year":"2023","journal-title":"J. Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1099\/0022-1317-79-5-1115","article-title":"Interaction between hepatitis delta virus-encoded proteins and hepatitis B virus envelope protein domains","volume":"79","author":"Hourioux","year":"1998","journal-title":"J. Gen. Virol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/3-540-29802-9_5","article-title":"Post-translational modification of delta antigen of hepatitis D virus","volume":"307","author":"Huang","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/infdis\/166.5.1164","article-title":"Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells","volume":"166","author":"Ilan","year":"1992","journal-title":"J. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100751","article-title":"Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression","volume":"5","author":"Jachs","year":"2023","journal-title":"JHEP Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u201creal world\u201d study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/liv.15467","article-title":"Natural history of untreated HDV patients: Always a progressive disease","volume":"43","author":"Kamal","year":"2023","journal-title":"Liver Int"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3851\/IMP2381","article-title":"Efficacy of pegylated interferon-\u03b1 treatment for 24 months in chronic delta hepatitis and predictors of response","volume":"18","author":"Karaca","year":"2013","journal-title":"Antivir Ther."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.15729","article-title":"Interferon alpha-2b therapy in chronic hepatitis delta","volume":"14","author":"Keshvari","year":"2014","journal-title":"Hepat Mon."},{"key":"B47","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years\u2019 bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J. Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2019.07.003","article-title":"Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients","volume":"71","author":"Loglio","year":"2019","journal-title":"J. Hepatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.13734","article-title":"HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response","volume":"44","author":"Niro","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J. Hepatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1055\/a-2133-8614","article-title":"Hepatitis delta infection: A clinical review","volume":"43","author":"Pearlman","year":"2023","journal-title":"Semin. Liver Dis."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28665","article-title":"Characterization of hepatitis virus co-infections in a cohort of immigrants living in southern Italy","volume":"95","author":"Pisaturo","year":"2023","journal-title":"J. Med. Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"S0168","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","year":"2023","journal-title":"J. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jhep.2023.02.041","article-title":"Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV\/HDV-prevalence countries","volume":"79","author":"Razavi","year":"2023","journal-title":"J. Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.3748\/wjg.v27.i42.7271","article-title":"Hepatitis B virus\/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic","volume":"27","author":"Sagnelli","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/jvh.13804","article-title":"and anti-HBc during bulevirtide treatment of chronic HDV-infected patients","volume":"30","author":"Sandmann","year":"2023","journal-title":"J. Viral Hepat."},{"key":"B59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","author":"Sandmann","year":"2023","journal-title":"Liver Int."},{"key":"B60","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2022.03.004","article-title":"Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV\/HDV-associated compensated cirrhosis","volume":"77","author":"Schwarz","year":"2022","journal-title":"J. Hepatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/00325481.2016.1175310","article-title":"Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study","volume":"128","author":"Soyer","year":"2016","journal-title":"Postgrad Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jhep.2019.12.028","article-title":"Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1","volume":"72","author":"Spaan","year":"2020","journal-title":"J. Hepatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","article-title":"The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation","author":"Stieger","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut."},{"key":"B68","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/S0168-8278(23)00606-2","article-title":"LBP-24 - Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trial","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature."},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEGinterferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J. Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl. J. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J. Viral Hepat."},{"key":"B76","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J. Infect. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1365-2893.2010.01353.x","article-title":"Natural history and treatment of chronic delta hepatitis","volume":"17","author":"Yurdayd\u0131n","year":"2010","journal-title":"J. Viral Hepat."},{"key":"B82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2018.02.021","article-title":"Hepatitis D virus replication is sensed by MDA5 and induces IFN-b\/k responses in hepatocytes","volume":"69","author":"Zhang","year":"2018","journal-title":"J. Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J. Hepatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1111\/liv.15408","article-title":"Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre","volume":"42","author":"Z\u00f6llner","year":"2022","journal-title":"Liver Int."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1382017\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T07:03:22Z","timestamp":1739257402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1382017\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":84,"alternative-id":["10.3389\/fcimb.2024.1382017"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1382017","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"article-number":"1382017"}}